CD274 and small cell lung carcinoma: Similar results were demonstrated in the CASPIAN (NCT03043872) study, when researchers investigated the PD-L1 inhibitor durvalumab with chemotherapy vs. chemotherapy alone in patients who had chemotherapy naïve ES-SCLC [23].